A Randomized, Two-cohort, Prospective Phase II Clinical Study of the Second-line Treatment of Advanced Biliary System Tumors With Liposomal Irinotecan (II) Combination Regimen
PHASE2
This is a randomized, two-cohort, multicenter Phase II clinical study. To e...
Status
Not Yet Recruiting
Location
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Real World Efficacy, Safety of Nanoliposomal Irinotecan With Fluorouracil and Folinic Acid in Metastatic Pancreatic Cancer After Previous Gemcitabine-based Therapy
N/A
The objectives of the study are to evaluate the efficacy (primary endpoint:...
Status
Completed
Location
CHU Bordeaux
Start Date
2023-10-06
Trial ID
NCT06006728
NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC
PHASE2
This study is a single-center, Phase II Study to assess the efficacy and sa...
Status
Recruiting
Location
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
A Randomized Controlled Study Comparing the Safety and Efficacy of Irinotecan Hydrochloride Liposome Injection Combined With Temozolomide and Vincristine (NALIRI-VT) Versus Irinotecan Combined With Temozolomide and Vincristine (VIT) in Patients With Advanced Ewing's Sarcoma
PHASE2
This study is a randomized, controlled, multicenter, prospective clinical t...